Adrenocortical Carcinoma News and Research

RSS

AI model predicts patient outcomes across multiple cancer types

Investigators from the UCLA Health Jonsson Comprehensive Cancer Center have developed an artificial intelligence (AI) model based on epigenetic factors that is able to predict patient outcomes successfully across multiple cancer types.

16 Nov 2023

Study shows not all adrenal carcinoma patients need mitotane after surgery

After the complete tumor resection, not all patients with an adrenocortical carcinoma require the previous standard therapy Mitotane. Professors Martin Fassnacht and Massimo Terzolo show this in a clinical trial.

25 Aug 2023

Novel molecular imaging radiotracer can precisely diagnose multiple cancers

A new molecular imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.

20 Nov 2022

Conceptual framework to examine the patterns of copy number alterations in human cancer

A new study published in Nature presented a conceptual framework to examine the patterns of copy number alterations in human cancer.

17 Jun 2022

Mutation-signature–associated metrics predict cancer progression in patients

Oncotarget published "Predicting clinical outcomes using cancer progression associated signatures" which reported somatic mutation signatures are an informative facet of cancer etiology, however they are rarely useful for predicting patient outcome.

28 Jun 2021

Study sheds new light on function and regulation of APOBEC3B in adrenocortical carcinoma

The cover for issue 36 of Oncotarget features, "Knockdown of APOBEC3B is associated with a lower tumor growth in an adrenocortical carcinoma xenograft mouse model," by Gara, et al. which reported that the role of APOBEC3B in adrenocortical carcinoma and the mechanisms through which its expression is regulated in cancer are not fully understood.

9 Sep 2020

Inherited mutation increases cancer risk among people of Brazilian descent

Scientists at St. Jude Children's Research Hospital alongside global partners are studying a common TP53-R337H variant found among people of Brazilian descent.

24 Jun 2020

Immunotherapy treatment shows promise for some patients with advanced rare cancers

A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity in patients with four types of advanced, hard-to-treat rare cancers.

20 Mar 2020

A small molecule can inhibit chemotherapy resistance of certain tumors

A team of researchers from the CNRS and Université Nice Sophia Antipolis has just shown that a small molecule called methiothepin can inhibit the chemotherapy resistance of certain tumors.

28 Jun 2018

Researchers identify new genetic drivers of adrenal cancer

Cancer researchers in Würzburg, in cooperation with the international Cancer Genome Atlas Research Network, have identified new genetic drivers of adrenal cancer. Würzburg was the center of coordination of the European scientists.

30 May 2016

Comprehensive genomic characterizations of ACC provide potentially better treatment options

An international team of scientists, including those at the Translational Genomic Research Institute (TGen), have discovered new avenues of potential treatments for a rare and deadly cancer known as Adrenocortical Carcinoma, or ACC.

11 May 2016

Study reveals important new findings about rare cancer

A study comprised of 39 international institutions revealed significant new findings about adrenocortical carcinoma (ACC), a rare cancer with an often poor prognosis.

10 May 2016

Endocrine Society urges physicians to increase screening for primary aldosteronism

The Endocrine Society today issued a Clinical Practice Guideline calling on physicians to ramp up screening for primary aldosteronism, a common cause of high blood pressure.

27 Apr 2016

Researchers test ATR-101 compound in clinical trial for adrenal cancer

One of the most challenging cancers to treat is also one of the rarest, which only adds to the challenge of finding potential new therapies.

16 Oct 2013

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

The Multiple Myeloma Research Foundation and Astellas Pharma Global Development, Inc. today announced that they have entered into a joint collaboration for the clinical development of OSI-906 in patients with relapsed multiple myeloma.

6 May 2011

Drug trial for OSI-906 begins

TGen Clinical Research Services at Scottsdale Healthcare today announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands.

23 Sep 2009

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company’s potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).

4 Sep 2009

Design of a compound that stabilizes the main natural suppressor of tumours

An interdisciplinary team of researchers, headed by Ernest Giralt at the Institute for Research in Biomedicine (IRB Barcelona) and Javier de Mendoza at the "Institut Catala d'Investigaciió Quimica" (ICIQ, Tarragona), have discovered a substance with the capacity to maintain protein p53 stable even when it presents certain mutations that promote the appearance of cancer.

14 Oct 2008